/Dexcom%20Inc%20HQ-by%20JHVEPhoto%20via%20Shutterstock.jpg)
Despite DexCom’s underperformance compared to its industry, Wall Street analysts remain optimistic about the stock’s prospects.
You don't need to be a stock market expert to earn above-average returns.
/Abbott%20Laboratories%20HQ%20photo-%20by%20Sundry%20Photography%20via%20iStock.jpg)
Despite Abbott’s recent underperformance over the past year, Wall Street analysts remain optimistic about the stock’s prospects.
/Abbott%20Laboratories%20vials%20and%20Logo-by%20Melniov%20Dmitriy%20via%20Shutterstock.jpg)
Abbott has underperformed the broader market over the past year, but Wall Street analysts are optimistic about the stock’s prospects.
Medtronic has underperformed the broader market over the past year, but Wall Street analysts are still moderately bullish about the stock’s prospects.
Despite Baxter International’s relatively underwhelming performance over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.
Boston Scientific has significantly outperformed the broader market YTD, and Wall Street analysts are still bullish about the stock’s prospects.
These three thematic ETFs could be potent growth vehicles in years to come.
These funds focus on U.S.-based companies in relatively stable industries.
These can be ideal buy-and-forget investments to add to your portfolio right now.